Spots Global Cancer Trial Database for Panobinostat and Sorafenib in Treating Patients With Liver Cancer That is Metastatic and/or Cannot Be Removed by Surgery

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Panobinostat and Sorafenib in Treating Patients With Liver Cancer That is Metastatic and/or Cannot Be Removed by Surgery

Official Title: Phase I Study of Combination of Sorafenib and LBH589 in Hepatocellular Carcinoma

Study ID: NCT00873002

Conditions

Liver Cancer

Interventions

panobinostat

sorafenib tosylate

Study Description

Brief Summary: RATIONALE: Panobinostat and sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Sorafenib may also stop the growth of liver cancer by blocking blood flow to the tumor. PURPOSE: This phase I trial is studying the side effects and best dose of panobinostat when given together with sorafenib in treating patients with liver cancer that is metastatic and/or cannot be removed by surgery.

Detailed Description: OBJECTIVES: Primary * Assess the safety and tolerability of panobinostat when combined with standard doses of sorafenib tosylate in patients with metastatic and/or unresectable hepatocellular carcinoma. * Determine the maximum tolerated dose of panobinostat when combined with standard doses of sorafenib tosylate in these patients. Secondary * Determine the response rate. * Determine the progression-free survival. * Determine the overall survival rate. OUTLINE: This is a dose escalation study of panobinostat. Patients receive panobinostat IV on days 1 and 8 and oral sorafenib tosylate twice daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. After completion of study therapy, patients are followed for 30 days.